Page last updated: 2024-11-12

lilopristone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lilopristone: structure given in first source; progesterone antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13490845
CHEMBL ID1908329
SCHEMBL ID940130
MeSH IDM0138966

Synonyms (24)

Synonym
97747-88-1
brn 5663600
estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxy-1-propenyl)-, (11-beta,17-beta,17(z))-
lilopristone
11beta-(p-(dimethylamino)phenyl)-17beta-hydroxy-17-((z)-3-hydroxypropenyl)estra-4,9-dien-3-one
lilopristone [inn]
lilopristona [spanish]
ccris 6529
zk 98.734
lilopristonum [latin]
lilopristona
3gl26h7n6t ,
lilopristonum
unii-3gl26h7n6t
CHEMBL1908329
11.beta.-(p-(dimethylamino)phenyl)-17.beta.-hydroxy-17-((z)-3-hydroxypropenyl)estra-4,9-dien-3-one
SCHEMBL940130
(8s,11r,13s,14s,17r)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-((z)-3-hydroxyprop-1-en-1-yl)-13-methyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
Q27257184
(8s,11r,13s,14s,17r)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(z)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
11beta-[4-(n,n-dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxyprop-1-(z)-enyl)-4,9(10)-estradien-3-one
A858612
DTXSID801034575
AKOS040744683

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Whether LIL and ONA share these latter two characteristics with MIF has not yet been determined but they illustrate properties that, in addition to diminished antiglucocorticoid activities and altered pharmacokinetic characteristics, warrant consideration during the development of these and never antiprogestational agents."( Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.
Benet, LZ; Jang, GR, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" No dose-response relationship was noted."( Termination of early pregnancy with ZK 98,734: pharmacokinetic behaviour and clinical effect.
Aedo, AR; Cekan, SZ; Kovács, L; Swahn, ML; Westlund, P, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID589115Mechanism based inhibition of human cytochrome P450 3A4 measured in vivo2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (32.61)18.7374
1990's27 (58.70)18.2507
2000's4 (8.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.04 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.08%)5.53%
Reviews9 (18.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (77.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]